

1 **Title Page**

2 **Title of the article:** HPV self-sampling among long-term non-attenders to cervical cancer  
3 screening in Norway: A pragmatic randomized controlled trial

4 **Author list:** Gunvor Aasbø<sup>1,2</sup>, Ameli Tropè<sup>3</sup>, Mari Nygård<sup>1</sup>, Irene Kraus Christiansen<sup>4</sup>,  
5 Ingrid Baasland<sup>3,5</sup>, Grete Alrek Iversen<sup>6</sup>, Ane Cecilie Munk<sup>7</sup>, Marit Halonen Christiansen<sup>8</sup>,  
6 Gro Kummeneje Presthus<sup>4</sup>, Karina Udem<sup>1,9</sup>, Tone Bjørge<sup>3,10</sup>, Philip E. Castle<sup>11,12</sup> and Bo  
7 Terning Hansen<sup>1,13</sup>

8 **Affiliations:**

9 <sup>1</sup>Department of Research, Cancer Registry of Norway, Oslo, Norway

10 <sup>2</sup>Institute of Health and Society, University of Oslo, Oslo, Norway

11 <sup>3</sup>Cervical Cancer Screening Programme, Cancer Registry of Norway, Oslo, Norway

12 <sup>4</sup>National HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital,  
13 Lørenskog, Norway.

14 <sup>5</sup>Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.

15 <sup>6</sup>Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway

16 <sup>7</sup>Department of Obstetrics and Gynaecology, Sørlandet Hospital Kristiansand, Kristiansand, Norway

17 <sup>8</sup>Department of Obstetrics and Gynaecology, Stavanger University Hospital, Stavanger, Norway

18 <sup>9</sup>National Institute of Occupational Health, Oslo, Norway

19 <sup>10</sup>Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

20 <sup>11</sup>Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA

21 <sup>12</sup>Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD,  
22 USA

23 <sup>13</sup>Department of Infection Control and Vaccine, Norwegian Institute of Public Health, Oslo, Norway

24

25 **Corresponding author:** Gunvor Aasbø, PhD, Department of Research, Cancer Registry of  
26 Norway, Oslo, Norway. Address: Postboks 5313 Majorstuen, 0304 Oslo, Norway  
27 [gunvor.aasbo@medisin.uio.no](mailto:gunvor.aasbo@medisin.uio.no), phone: +47 482 57 136

28 OrcID: 0000-0002-8981-5374

29

30

31

32

33

34

35

36

37

38

39

1 **Keywords:** screening participation, cervical cancer, self-sampling, RCT, human  
2 papillomavirus

3

4 **Abstract:**

5 **Background:** The main aim of the present study is to assess whether human papillomavirus  
6 (HPV) self-sampling may increase cervical cancer screening participation among long-term  
7 non-attenders in Norway.

8 **Methods:** A pragmatic randomized controlled trial was initiated in the national cervical  
9 screening programme in March 2019. A random sample of 6000 women aged 35-69 years  
10 who had not attended screening for at least 10 years were randomized 1:1:1 to receive either  
11 (i) a reminder to attend regular screening (control arm), (ii) an offer to order a self-sampling  
12 kit (opt-in arm), or (iii) a self-sampling kit unsolicited (opt-out arm).

13 **Results:** Total screening participation during 6 months following study invitation was 4.8%,  
14 17.0% and 27.7% among women who received a standard reminder letter (controls), women  
15 who could order a self-sample kit (opt-in) and women who received a self-sample kit  
16 unsolicited (opt-out), respectively ( $P < 0.0001$ ). High-risk HPV was detected in 11.5% of the  
17 self-samples and in 9.2% of the clinician-collected samples ( $P = 0.40$ ). Most women (92.5%)  
18 who returned a positive self-sample attended triage. Of 933 women screened in the study (by  
19 a clinician or HPV self-sampling), 33 (3.5%) had CIN2+, 31 (3.3%) had CIN3+, and 11  
20 (1.2%) had cervical cancer.

21 **Conclusion:** We conclude that opt-in and opt-out self-sampling increased screening  
22 participation among long-term non-attenders.

23 **Clinical Trial Registration:** ClinicalTrials.gov NCT03873376

24

## 1 **Background**

2 Screening has reduced cervical cancer incidence (1) and mortality (2) substantially in  
3 Norway. However, coverage of the national cervical cancer screening programme has  
4 stagnated at a suboptimal 70% (3), and cervical cancer incidence has increased by 14% from  
5 the period 2009-2013 to 2014-2018 (3). Under- or unscreened women have an increased risk  
6 of cervical cancer (4) and being diagnosed at an advanced stage (5). Thus, interventions that  
7 improve screening participation would benefit women's health.

8 Approximately 17% of women aged 35-69 years in Norway have not been screened for at  
9 least 10 years (3). In Sweden, the detection of high-grade cervical abnormalities among  
10 women who had not been screened during the last 10 years was considerably higher than in  
11 the general screening population (6), which highlights the need for improved interventions  
12 among long-term non-attenders. Important reasons for non-attendance include procrastination,  
13 embarrassment, fear of pain and previous negative experiences with the gynaecological exam  
14 or a history of sexual abuse (6, 7), as well as practical barriers experienced in everyday life  
15 (8). Non-attendance among Norwegian women is also associated with having a  
16 male/foreign/young general practitioner (GP) (9), lacking awareness of the recommended  
17 screening interval (10), and lower socioeconomic or migrant background (11). Self-sampling  
18 for human papillomavirus (HPV) testing, which the women can perform themselves at home,  
19 may reinforce the importance of screening, empower women, and mitigate some of the  
20 barriers associated with attending a gynaecological screening exam.

21 HPV infection is a necessary cause of cervical cancer (12). A persistent infection with high-  
22 risk HPV (hrHPV) may, through intermediate precancerous stages, lead to cancer (13).  
23 Moreover, when cervical cancer is detected at a late stage, effective treatment is limited and  
24 prognosis poor (14). When used with HPV assays based on polymerase chain reaction (PCR),  
25 self-sampling and HPV testing identifies women with cervical precancer and cancer, cervical  
26 intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+), with similar accuracy as  
27 clinician-collected samples (15). Studies also show that self-sampling has a high acceptability  
28 among women and is preferred over clinician sampling (16). Opt-out strategies, where women  
29 receive a self-sampling kit unsolicited, proved to increase screening participation of under-  
30 screened women in a relatively recent meta-analysis (15), and in Norway (17). Opt-in  
31 strategies, where women must request a self-sampling kit, have generally not been found to be  
32 more effective than invitation letters for increasing screening participation. The effect of self-

1 sampling on participation varies between studies, especially for opt-in strategies, and warrant  
2 more studies (15).

3 Studies on the effect of HPV self-sampling on participation among under-screened women  
4 often include women only slightly overdue for screening, who may be easier to engage than  
5 long-term non-attenders, while few randomized controlled trials have by design specifically  
6 targeted long-term non-attenders (6, 18-21). It is important to gain more knowledge on how  
7 secondary cancer prevention among long-term non-attenders may be improved because they  
8 may be at a relatively high risk for CIN2+.

### 9 *Aim*

10 The primary aim of this study was to compare cervical cancer screening participation among  
11 women in Norway who have not attended screening for at least 10 years, who received either  
12 a standard reminder letter to attend screening in a clinic (control arm), an offer to order an  
13 HPV self-sampling kit (opt-in arm), or were sent an unsolicited HPV self-sampling kit (opt-  
14 out arm). As secondary endpoints, we estimated hrHPV positivity rates, attendance to triage  
15 after an HPV positive self-sample, and occurrence of CIN2+ among the long-term non-  
16 attenders who participated in screening.

17

## 18 **Materials and Methods**

### 19 *Cervical screening in Norway*

20 The Cancer Registry of Norway (CRN) is responsible for the national cervical cancer  
21 screening programme (NCCSP), and invites women aged 25 to 69 years to attend screening.  
22 The programme is currently transitioning from cytology every three years to HPV primary  
23 screening every five years for women aged 34-69 years. NCCSP uses a centralised invitation  
24 procedure and issues standard open reminder letters to women who have not been registered  
25 with a screening test during the recommended interval. A second reminder is issued after one  
26 year if a woman is still not registered with a test result. These reminders encourage women to  
27 schedule an appointment with their GP for a screening test. All cytology and HPV screening  
28 results, as well as any associated histology results, are registered in the NCCSP database. All  
29 records are associated with the personal identity number unique to each Norwegian resident.

### 30 *Study population and design*

1 The target population was women residing in the counties of Hordaland, Rogaland, Sør-  
2 Trøndelag and Vest-Agder who had not participated in the screening programme for the last  
3 10 years. These regions consist of mixed rural and urban areas and cover about one-third of  
4 the Norwegian population. During the study, primary screening was offered by HPV-test in  
5 Hordaland, Rogaland and Sør-Trøndelag, and by cytology in Vest-Agder. A priori power  
6 calculations showed that we needed at least 1417 women in each intervention arm to detect a  
7 difference of 5 percentage points between the control arm and the intervention arms with 90%  
8 power. Using the NCCSP database, we identified 28,125 women who were eligible for the  
9 study, of which 6000 (21.3%) were randomly selected for invitation to the study. The  
10 randomly selected women were individually randomized 1:1:1 into the control, opt-in or opt-  
11 out intervention arm without further restrictions. The eligible women were unaware of the  
12 randomization. Blinding was not possible due to the nature of the interventions.  
13 Randomization procedures were performed using the sample function in Stata by a  
14 programmer who was not involved in the conduct of the trial. Invitations were sent during  
15 March-August 2019.

16 A total of 333 (5.6%) invited women, similarly distributed by intervention arm; 108 (5.4%) in  
17 the control arm, 103 (5.1%) in opt-in arm, and 122 (6.1%) in opt-out arm;  $P = 0.4$ ), were  
18 excluded from the study due to: (i) incorrect address, (ii) active refusal to participate in the  
19 study, or (iii) ineligibility for the study (living abroad/had prior hysterectomy/had a screening  
20 test between study sampling and invitation) (see Figure 1). The trial was registered at  
21 ClinicalTrials.gov on 8 March 2019 (NCT03873376).

#### 22 *Invitation letters and information*

23 Women in the control arm received a NCCSP reminder letter to attend regular screening (i.e.,  
24 encouraging the women to schedule an appointment with their GP). The letter also stated that  
25 they were randomly selected to participate in a study aiming to improve cervical cancer  
26 prevention. The letter included no information about self-sampling.

27 Women in the opt-in arm received an invitation letter to order a self-sampling kit. The women  
28 could order by mail, e-mail, or through a webpage. The invitation included a unique order  
29 code, information about the study, a reply slip, and a pre-paid envelope to return the order. A  
30 dedicated webpage for ordering a self-sampling kit was available in Norwegian, English,  
31 French, Spanish, Polish, Turkish and Arabic. Each order code could only generate one web  
32 order.

1 A self-sampling kit was mailed unsolicited to women in the opt-out arm, together with the  
2 study invitation letter. The content in the opt-in and opt-out invitation letters was the same  
3 (apart from the description of the ordering procedure in the opt-in letter) and included  
4 information that the women alternatively could schedule a regular screening appointment with  
5 their GP if they did not want to use the self-sample.

6 Similar to regular NCCSP reminders, all invitation letters contained general screening  
7 information. The letters were on NCCSP stationary and were signed by the NCCSP head. In  
8 addition, letters contained study-specific information, a link to the study webpage, and  
9 information that they could refrain from participating in the study. All invitation letters were  
10 in Norwegian, except for an English reference to a webpage. The study webpage was  
11 available in Norwegian and English and included a link to an instructional video on how to  
12 collect a self-sample with options for Norwegian or English audio, and English, French,  
13 Spanish, Polish, Turkish or Arabic subtitles.

#### 14 *The HPV self-sampling kit*

15 The kit included the self-sampling device with user instructions, a sealable plastic bag, a  
16 prepaid return envelope addressed to the laboratory, and an information leaflet. The Evalyn®  
17 Brush (dry brush) (Rovers Medical Devices B.V, Oss, Netherlands) was used for self-  
18 sampling in this study. The self-sampling device had a hidden radio frequency identification  
19 chip containing a pseudonymized number unique to each invited woman and had no visible  
20 personal information. Women returned the self-sample in the plastic bag and mailed it in the  
21 return envelope. Women who had not ordered/returned a self-sample within three weeks  
22 received one reminder letter to order/return the self-sample. The self-sampling kit was free of  
23 charge for the women.

#### 24 *HPV detection from self-sampled screening test*

25 All self-samples were analysed at the Norwegian HPV reference laboratory at Akershus  
26 University Hospital. Soon after receipt at the laboratory, the brush tip was removed from the  
27 self-sampling device, transferred to a vial with 4.5 mL ThinPrep PreservCyt and stored at  
28 room temperature for at least 24 hours. During storage, tubes with the brush tip were vortexed  
29 three times for 15 seconds to ensure proper dissolution of the sample material. The samples  
30 were tested for hrHPV using the cobas® 4800 HPV test (Roche Molecular Systems, Inc,  
31 Branchburg, NJ), which individually reports HPV16 and HPV18, in addition to a pooled  
32 result of the 12 hrHPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Beta-globin is

1 included as internal quality control in a fourth channel. Samples with an invalid test result at  
2 first run were retested, which gave a valid test result in every case. Analysis was completed  
3 within 21 days after receipt for all samples.

#### 4 *Clinical management*

5 All women who returned a self-sample were informed about their test result per ordinary mail  
6 within six weeks after receipt of the self-sample in the lab. Women with an HPV negative  
7 result were encouraged to continue attending the regular cervical cancer screening programme  
8 at the recommended interval. Women with a hrHPV positive self-sample received the result  
9 together with a pre-booked triage appointment with a physician. To address feasibility and  
10 performance of alternative triage strategies that could be implemented in a screening  
11 programme, women were sequentially allocated to triage at their GP or a gynaecologist  
12 practicing in the largest city in their county. The notification letter to women in each group  
13 was identical. Physicians were informed that the patient had tested positive for HPV after  
14 participating in a study offering HPV self-sampling to long-term non-attenders. Women  
15 referred to GP triage underwent cytology, while women referred to gynaecologist triage  
16 underwent further gynaecological examination, which always included cytology and  
17 colposcopy, and biopsy if deemed necessary. To simulate a routine healthcare setting, the  
18 women paid the deductible for the GP or the gynaecologist appointment themselves (about  
19 30€ and 60€ respectively), as they would in the NCCSP. Management after the scheduled  
20 triage visit of women who had a positive hrHPV self-sample was not specific for the study  
21 and thus follow national guidelines (22). Similarly, women who had a clinician-collected  
22 screening sample (irrespective of treatment arm), or who had a triage cytology with another  
23 physician than she was allocated to in the study were managed outside the study. According  
24 to the national screening algorithm, women who are HPV16/18 positive are referred to  
25 colposcopy with biopsy if the cytology is low- or high-grade, or to a new HPV-test in 12  
26 months if the cytology is normal. Women who are positive for other hrHPV-types are referred  
27 to colposcopy with biopsy if cytology high-grade, to a new HPV-test in 12 months if cytology  
28 low-grade, or to a new HPV-test in 24 months if cytology normal. Cytology is reported  
29 according to the Bethesda system.

#### 30 *Registry data collection*

31 Data regarding clinician-collected screening tests (including triage tests taken outside the  
32 study) was taken from the NCCSP database. Data on histological outcomes from colposcopy



1 referrals were taken from the NCCSP and the CRN databases. Dates were delivered by month  
2 and year. If several histological diagnoses were available for the same women, we only  
3 considered the most severe diagnosis. The last registry linkage was performed in December  
4 2020, which allowed at least 16 months of registry follow-up after study invitation. Histology  
5 diagnoses were interpreted according to WHO guidelines (23). Income data was collected by  
6 linkage to Statistics Norway.

### 7 *Statistical analysis*

8 Screening participation was defined as returning a valid self-sample or having a clinician-  
9 collected screening test within six months after receipt of the invitation letter. Attendance to  
10 triage was assessed among women with a hrHPV positive self-sample and was defined as  
11 attending at the allocated physician (i.e., GP or study gynaecologist) or an unallocated  
12 physician within six months of notification of a positive self-sample. Women who returned a  
13 hrHPV positive self-sample and who were not registered with a cytology test by three months  
14 following the scheduled appointment, received a reminder from the NCCSP encouraging  
15 them to order an appointment at their GP.

16 We present numbers and proportions of screening participation by intervention arm  
17 (control, opt-in, opt-out) overall, by age groups (36-45, 46-55, 56-65, 66-69) and by screening  
18 history (time since last screening test 10-15 years, 16-28 years, never). For each self-sampling  
19 arm, we present total participation as well as clinician-sampled and self-sampled participation  
20 separately. Controls were only screened by a clinician. Differences in screening participation  
21 among intervention arms are presented for total participation (i.e., intention to treat), as  
22 absolute participation differences (APD, percentage points) and as relative participation  
23 differences (RPD, relative risks) with associated 95% confidence intervals (95% CI). Further,  
24 we present numbers and proportions of hrHPV positive screening tests and histologically  
25 verified high-grade lesions by intervention arm. To investigate the diagnostic yield by mode  
26 of triage, we also present the histologically verified high grade lesions separately for women  
27 triaged by study gynaecologists, women triaged by study GPs, and women who had a  
28 clinician-collected screening test or attended triage outside the study (i.e., women not  
29 managed by a study gynaecologist/GP). Since women who have a clinician-collected  
30 screening test do not need a separate triage visit, attendance to triage is only presented for  
31 women who tested positive by self-sampling. We present attendance to triage by self-  
32 sampling arm and by mode of triage (i.e., at gynaecologist or GP). For comparisons of counts  
33 and proportions, P-values refer to chi-squared tests, or the Fisher's exact test for observed



1 counts <5. For comparisons of central tendency, P-values refer to the Mann-Whitney U-test.

2 All tests were two-sided and P-values <0.05 were considered statistically significant.

3 Analyses were performed using Stata version 17MP or R version 3.5.3.

4

## 5 **Results**

6 All baseline characteristics addressed in the study cohort were similarly distributed by study  
7 arm (Table 1). The mean age was 54.5, 54.4 and 54.1 years among women in the control, opt-  
8 in and opt-out arm. Similar frequency distributions in each study arm were observed for  
9 categories of age (P=0.94), time since last screen (P=0.99), county of residence (P=0.96) and  
10 income (P=0.28) (Table 1).

11 Total participation (i.e., self-sampled and clinician-sampled tests for the self-sampling arms)  
12 was 4.8% in the control arm, 17.0% in opt-in arm and 27.7% in opt-out arm (P < 0.0001,  
13 Figure 2, Table 2). Thus, absolute participation differences and relative participation  
14 differences in total participation was: 12.3% (95% CI 10.3 - 14.2) and 3.6 (95% CI 2.9 - 4.5),  
15 respectively for opt-in vs. controls; 22.9% (95% CI 20.7 - 25.2) and 5.8 (95% CI 4.7 - 7.2),  
16 respectively, for opt-out vs. controls; and 10.7% (95% CI 8.0 - 13.3) and 1.6 (95% CI 1.4 -  
17 1.8), respectively, for opt-out vs. opt-in. Differences in participation between intervention  
18 arms were largely due to self-sampling use, since there was similar attendance to clinician-  
19 collected screening: 4.8% for the control arm, 3.8% for opt-in, and 4.0% for opt-out (P = 0.33,  
20 Table 2).

21 In the opt-in arm, 403 out of 1897 (21.2%) women ordered a self-sample, of which 144  
22 (35.7%) ordered after receiving a reminder, and 250 (13.2%) returned the self-sample for  
23 analysis. Opt-in orders were made by ordinary mail (51.6%), web (33.0%), e-mail (14.2%) or  
24 telephone to the study centre (1.2%; not presented as an option in the invitation letter).  
25 Among 445 women in the opt-out arm who submitted a self-sample, 254 (57.1%) did so after  
26 receiving a reminder.

27 Self-sampling increased total participation in all age groups and screening history categories.  
28 Total participation was consistently highest in the opt-out arm, intermediate in the opt-in arm  
29 and lowest in the control arm (Table 2). In each arm, total participation was highest in the  
30 youngest age group (age 36-45 years), at 8.0%, 18.5% and 32.9% among controls, opt-in and  
31 opt-out, respectively, and tended to decrease with age (P-trend in total participation by age

1 group: 0.001, 0.15 and 0.002 for controls, opt-in and opt-out, respectively). Participation  
2 generally decreased with increasing time since last screening test, and this pattern was evident  
3 for both clinician-sampling and self-sampling, and in each intervention arm (P-trend in total  
4 participation by time since last screening test (10-15 years, 16-28 years or never screened):  
5 <0.0001, <0.0001 and 0.004 for controls, opt-in and opt-out, respectively). Among women  
6 who never had been screened previously, total participation was 1.9% for controls, 11.4% for  
7 opt-in and 25.0% for opt-out ( $P < 0.0001$ ). Also, the RPD was highest among never screeners,  
8 at 6.1 (95% CI 3.4 - 11.1), 13.4 (95% CI 7.5 - 23.8) and 2.2 (95% CI 1.7 - 2.8) for opt-in vs.  
9 controls, opt-out vs. controls and opt-out vs. opt-in, respectively (Table 2).

10 Among all women who were tested for HPV, 11.0% were positive for any hrHPV. The  
11 hrHPV positivity rate was slightly higher for self-sampled tests than for clinician-collected  
12 tests, at 11.5% and 9.2% respectively ( $P = 0.40$ , Table 3). Among controls, 6.0% were  
13 positive for any hrHPV, which was non-significantly lower than observed among women in  
14 the opt-in (10.8%) and opt-out (11.8%) intervention arms ( $P = 0.28$ ) (Table 3).

15 Triage attendance was similar in the opt-in and opt-out arms, at 77.8% and 79.3% ( $P = 1$ ),  
16 respectively, for scheduled attendance, and 92.6% and 92.5% ( $P = 1$ ), respectively, for any  
17 attendance within six months (Table 4). Attendance for women allocated to gynaecologist  
18 triage (irrespective of intervention arm) for scheduled and any attendance was 75.6% and  
19 90.2%, respectively, which was non-significantly lower than observed among women  
20 allocated to GP triage, who had corresponding attendance of 82.1% and 94.9% ( $P = 0.67$  for  
21 scheduled attendance,  $P = 0.72$  for any attendance, Table 4). The median (interquartile range  
22 (IQR)) period between a positive self-sample and the scheduled triage appointment was  
23 shorter for women allocated to GP triage than gynaecologist triage, at 19 (IQR 14, 25) and 43  
24 (IQR 29, 54) days ( $P < 0.0001$ ), respectively. However, among women who were biopsied  
25 and had a histology result, the median (IQR) period between the positive self-sample and the  
26 histological diagnosis was longer for women who were allocated to and attended GP triage  
27 than for women who were allocated to and attended gynaecologist triage, at 4 (IQR 3, 8) and  
28 3 (IQR 2, 3) months, respectively ( $P = 0.01$ ).

29 A total of 1, 12, and 20 prevalent cases of CIN2+ were detected in the control, opt-in, and opt-  
30 out arms, respectively (Table 5). Thus, we detected CIN2+ in 0.1%, 0.6% and 1.1% of the  
31 invited women ( $P = 0.0002$ ), and in 1.1%, 3.7% and 3.8% of the screened women ( $P = 0.52$ )  
32 in the control, opt-in, and opt-out arms, respectively. A total of 0, 4 and 7 cases of cervical  
33 cancer were detected in the control, opt-in and opt-out arms, respectively, giving

1 corresponding detection rates per woman screened of 0%, 1.2% and 1.3% ( $P = 0.81$ ). In each  
2 of the self-sampling arms, the detection rate of CIN2+ and cancer per woman screened was  
3 similar among women who screened by self-sampling and women who attended screening at  
4 a clinic (Table 5).

5 A relatively high proportion of women with screening-positive tests were subsequently  
6 diagnosed with CIN2+ (Table 6). Although the percentage of histologic diagnoses was higher  
7 in the group attending gynaecologist triage, the CIN2+ yield was similar in this group when  
8 compared to women attending GP triage and women who were screened in a clinic or were  
9 triaged outside the study, at 32.3%, 34.4% and 35.3% of the screening-positive tests,  
10 respectively. Similar occurrence was observed for CIN3+, thus few of the histologically  
11 verified cases were CIN2, an equivocal diagnosis of precancer (24). Cancer was diagnosed in  
12 four women who attended gynaecologist triage, four women who attended GP triage, and  
13 three women who attended screening at a clinic or triage outside the study, which constituted  
14 12.9%, 12.5% and 8.8% of the screening-positive tests respectively. For all screening and  
15 triage modes, the CIN2+ yield was considerably higher among women who tested positive for  
16 HPV16/18 than among women who were positive for other hrHPV types. Among women  
17 who screened positive for HPV16/18, the percentage of CIN2+ was 64.3%, 55.6% and 69.2%  
18 for women attending gynaecologist triage, GP triage, and women who attended screening at a  
19 clinic or triage outside the study, respectively (Table 6).

## 20 **Discussion**

21 We show that offering HPV self-sampling to long-term non-attending women as opt-in or as  
22 opt-out significantly increases the cervical screening participation relative to the standard  
23 reminder letter, and that opt-out gives the largest increase in participation.

24 Although the effect of self-sampling interventions may differ between studies due to  
25 differences in study design and screening setting, increased participation by the opt-out self-  
26 sampling strategy is well established compared to clinician-collected screening (15, 25). In  
27 the present study, we observed larger absolute and relative differences in participation  
28 between the opt-out self-sampling arm and the controls than was reported in a recent meta-  
29 analysis of self-sampling (15). Moreover, we observed significantly increased participation  
30 for the opt-in strategy, which was not found in the meta-analysis (15). Our results regarding  
31 self-sampling participation generally coincide with randomized controlled trials that have

1 targeted long-term non-attenders (6, 18-20) or show stratified analyses for this part of the  
2 screening population (21, 26).

3           Characteristics of the targeted screening population are important for the way in which  
4 self-sampling interventions may affect participation. When self-sampling is offered more  
5 widely to women who are overdue for screening, it tends to replace screening at a clinic in  
6 addition to increase overall participation (17, 21). We observed that the clinician-collected  
7 screening uptake was only marginally lower in the self-sampling arms than in the control arm,  
8 indicating that self-sampling hardly replaces clinician-collected screening when offered  
9 exclusively to long-term non-attenders. Our observation that some long-term non-attending  
10 women offered self-sampling still preferred to be screened by a clinician, demonstrates the  
11 importance of maintaining this option even if self-sampling is implemented in the Norwegian  
12 screening programme. Overall, we report similar effects on participation as a Swedish study  
13 targeting long-term non-attenders (6). However, the absolute increases in participation for the  
14 self-sampling interventions versus controls were considerably higher in our study, but the  
15 relative participation difference was lower, which may relate to the slightly different  
16 screening contexts experienced by long-term non-attending women in these countries. For  
17 instance, the Swedish screening programme issues far more screening reminders than the  
18 Norwegian programme and offers prescheduled screening appointments rather than an  
19 encouragement to order an appointment for screening, which in part may explain the higher  
20 coverage observed for ordinary screening in Sweden (4) and the very low participation to  
21 clinician-collected screening among long-term non-attenders (6). On a general note, groups  
22 that respond poorly to the control intervention, i.e. the standard invitation to attend screening  
23 in a clinic, have a high potential to benefit from self-sampling in relative terms, as we can  
24 observe in the relative participation difference estimates of the never-screeners and the  
25 women in the oldest age brackets in our study population.

26           Although inferior to opt-out, we found that opt-in also increased screening  
27 participation when compared to controls who received the routine reminder letter. Thus, this  
28 type of intervention should not be dismissed, although opt-in in other settings often did not  
29 improve participation beyond a routine reminder letter to screen (15). The way in which this  
30 intervention is offered may be of particular importance for achieving increased participation.  
31 The present study results suggest that alternative ordering options that include ordinary mail  
32 and a web-solution may be considered for opt-in among long-term non-attenders, and that a  
33 reminder to order the self-sampling device may be effective. Some effect of opt-in has also

1 been reported in intention-to-treat analyses of other randomized controlled trials (6, 21) and  
2 observational studies (27, 28) in Scandinavia.

3 Long-term non-attending women may be hesitant to undergo a gynaecological  
4 examination for screening purposes (29), but our study showed that the vast majority attended  
5 to examination by a physician if they submitted a positive self-sample. The attendance to  
6 triage observed among women with a positive hrHPV self-sample was somewhat higher than  
7 attendance to follow-up after positive screening tests in the NCCSP (3). A high attendance to  
8 triage after a positive self-sample has also been found in other settings (15). We found that  
9 triage attendance was similar for women who were scheduled for GP and gynaecologist  
10 triage. However, some women chose to be triaged by another physician than they were  
11 allocated to in the study, and this happened slightly more often among women allocated to a  
12 gynaecologist than among women allocated to their GP. One reason for this difference could  
13 be that the gynaecologists on average were located further away from the women than their  
14 GP. Moreover, we observed a longer time lag between notification and the scheduled  
15 appointment for women allocated to a gynaecologist, which could have compelled more of  
16 these women to reschedule to a physician who could offer an earlier appointment.

17 The hrHPV positivity rate of the total study population of long-term non-attenders was  
18 nearly twice as high as the corresponding rate among women of the same age in the ordinary  
19 screening population (3). In both self-sampling arms, women who chose to attend screening at  
20 a clinic and women who chose to use self-sampling had similar hrHPV positivity rates,  
21 indicating that the mode of screening chosen by long-term non-attending women is not  
22 associated with risk of infection.

23 Due to low numbers, the CIN2+ occurrence observed here should be interpreted with  
24 caution, especially in terms of comparisons between intervention arms or other subgroups.  
25 Among all the long-term non-attending women who were screened during the study, 3.5%  
26 and 1.2% were diagnosed with CIN2+ and cervical cancer, respectively, while the  
27 corresponding rate among women aged 34-69 years in the NCCSP is 1.2% and 0.1% (3).  
28 Thus, CIN2+ and cervical cancer yield among long-term non-attenders observed in this study  
29 was very high compared to the ordinary screening population, which probably reflects a real  
30 difference in risk. However, surveillance bias could also have contributed since most  
31 physicians who triaged women who had submitted a hrHPV-positive self-sample knew that  
32 they were long-term non-attenders and part of a study, and women who were triaged by a  
33 study gynaecologist underwent colposcopy at the triage visit. However, the occurrence of

1 CIN2+ among women with a positive screening test (hrHPV or cytology) was very similar  
2 regardless of differences in diagnostic follow-up.

3 GP and gynaecologist triage of long-term non-attending women who had a hrHPV-  
4 positive self-sample gave similar attendance and diagnostic yield. However, for long-term  
5 non-attending women who have CIN2+, it is important to be treated quickly, and our results  
6 clearly showed that the final diagnostics appeared earlier if women were referred directly to a  
7 gynaecologist who could perform a colposcopic biopsy at the triage visit than if they were  
8 referred to their GP for cytology triage. Furthermore, the CIN2+ and CIN3+ detection rates  
9 among long-term non-attenders with a positive screening test exceeded the risk thresholds for  
10 which colposcopy usually is considered good practice (30, 31).

### 11 **Strengths and limitations**

12 A strength of the present study is the use of national registry data that ensures a precise  
13 definition of the study cohort and complete information on participation and diagnostics.  
14 Targeted sampling of long-term non-attenders also ensures a sufficient sample size for robust  
15 inference regarding comparisons of participation by study arm in this part of the screening  
16 population. Another strength is the randomized design that enhances the representativeness of  
17 the study sample and the similarity of the intervention arms. The intervention arms should  
18 thus be highly comparable, and the results of the present study should have high  
19 generalizability to the population of long-term non-attenders in Norway. Furthermore, we  
20 used a self-sampling device and a PCR-based HPV DNA test that were clinically validated  
21 and gave no invalid self-samples in this study. Finally, the trial was embedded in the NCCSP,  
22 which should make the study results relevant to a real-world scenario where self-sampling is  
23 offered as part of an organized programme. However, the invited women were informed that  
24 this was a study, which could have influenced their motivation to participate. A further  
25 limitation is the relatively low subgroup numbers regarding hrHPV positivity, attendance to  
26 triage and CIN2+ occurrence, which limits the precision of the inference that can be made  
27 regarding these secondary outcomes of the study.

28

### 29 **Conclusion**

30 We conclude that opt-in and opt-out self-sampling strategies increase screening participation  
31 among long-term non-attenders to cervical screening in Norway. If implemented as part of the

1 screening programme, both strategies would probably improve secondary prevention of  
2 cervical cancer and thus benefit women's health. Long-term non-attenders also have an  
3 elevated risk for hrHPV infection and high-grade cervical lesions, which highlights the large  
4 potential to improve cervical cancer prevention by increasing the screening participation of  
5 this population. The opt-out strategy would maximize the preventive effect because it clearly  
6 increased participation the most. Maintaining an offer for clinician-collected screening will  
7 still be important, since some long-term non-attenders offered self-sampling preferred this  
8 option. We also show that management of hrHPV-positive self-samples by GP cytology triage  
9 or direct referral to colposcopy by gynaecology specialists give similar results in terms of  
10 triage attendance and diagnostic yield. Our study supports findings that direct referral to  
11 colposcopy might be the best option for hrHPV-positive women in this population, especially  
12 if they are positive for HPV16/18, because they are at a relatively high risk for sequelae and  
13 colposcopy referral gives the shortest lag to a histologically confirmed diagnosis and  
14 treatment. Colposcopy is generally a safe procedure, thus over-referral will not be a burden  
15 for the patient.

16

## 17 **Additional Information**

18 Acknowledgements: We thank Mona Hansen for valuable contribution in the planning and  
19 preparation of procedures for sample and data handling at the laboratory; Suzanne Campbell  
20 and Kristina S. Gjøtterud for data management; Kristin H. Brenden, Gintaras Pikelis, Håkan  
21 Olofsson, Caroline Skudal and Björn Eklund for IT design and support; Randi Waage and Gry  
22 B. Skare for NCCSP support; Pia C.M. Osborne and Minh T. Le for data collection  
23 assistance, and Jeanette Hoel who was the user representative of the study.

24 Authors' contributions: BTH, MN and AT conceived the study. GA, IKC, TB and PEC  
25 contributed to the study design. BTH was the principal investigator. BTH, GA and KU  
26 coordinated the execution of the trial. IKC supervised sample flow and HPV-testing. BTH and  
27 GA were responsible for data analyses. IB, GAI, ACM, MHC and GKP contributed to data  
28 collection. GA wrote the first manuscript draft with support from BTH. All authors  
29 commented on drafts and approved the final manuscript.

30 Ethics approval and consent to participate: The South-Eastern Committee A for Medical and  
31 Health Research Ethics in Norway approved the study (project-ID: 2019/111) and Oslo  
32 University Hospital Data Protection Officer approved the processing of data in the study



1 (project-ID: 18/14056). In addition, a statement regarding the processing of personal data was  
2 also obtained from the Data Protection Officer at Akershus University Hospital. For women  
3 in self-sampling arms, the invitation included information that by returning the self-sample,  
4 they consented to the subsequent procedures described in the invitation letter. All invited  
5 women, including those in the control arm, were informed that they could withdraw from the  
6 study at any time. The study was performed in accordance with the Declaration of Helsinki

7 Consent for publication: Not applicable

8 Data availability statement: The data contains personal information and the study participants  
9 have not consented to public data sharing. Data access requires permission by relevant  
10 Norwegian authorities.

11 Competing Interests: Dr. Castle has received HPV tests and assays for research at a reduced  
12 or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. All other  
13 authors declare no conflict of interest.

14 Funding information: This study was funded by the Norwegian Cancer Society and Thea  
15 Steen Memorial fund (grant number 182687-2016). The funding source had no role in study  
16 design, data collection and analysis, preparation of the manuscript, or decision to publish.

17 Disclaimer: The opinions expressed by the authors are their own and this material should not  
18 be interpreted as representing the official viewpoint of the U.S. Department of Health and  
19 Human Services, the National Institutes of Health, or the National Cancer Institute.

20

## 21 **References**

- 22 1. Lönnberg S, Hansen BT, Haldorsen T, Campbell S, Schee K, Nygård M. Cervical  
23 cancer prevented by screening: Long-term incidence trends by morphology in Norway. *Int. J.*  
24 *Cancer* 2015;137, 7: 1758-64.
- 25 2. Haldorsen T, Skare GB, Steen R, Thoresen SO. Livmorhalskreft etter ti års offentlig  
26 koordinert screening. [Cervical cancer after 10 years of nationally coordinated screening].  
27 *Tidsskr. Nor. Lægefor.* [Journal of the Norwegian Medical Association.] 2008;128, 6: 682-85.
- 28 3. Cancer Registry of Norway. Annual rapport 2019, Screening Activity and Results  
29 from the National Cervical Cancer Screening Programme, [Årsrapport 2019,  
30 Screeningaktivitet og resultater fra Livmorhalsprogrammet]. 2020. Available:

- 1 <https://www.kreftregisteret.no/globalassets/livmorhalsprogrammet/rapporter/arsrapport->
- 2 [lp/arsrapport-livmorhalsprogrammet-2019v2\\_sept2021.pdf](https://www.kreftregisteret.no/globalassets/livmorhalsprogrammet/rapporter/arsrapport-livmorhalsprogrammet-2019v2_sept2021.pdf) [Accessed 10 Febr. 2022].
- 3 4. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et. al. Screening-
- 4 preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *J Natl Cancer*
- 5 *Inst* 2008;100, 9: 622-9.
- 6 5. Pedersen K, Burger EA, Campbell S, Nygård M, Aas E, Lönnberg S. Advancing the
- 7 evaluation of cervical cancer screening: development and application of a longitudinal
- 8 adherence metric. *Eur. J. Public Health* 2017;27, 6: 1089-94.
- 9 6. Elfström KM, Sundström K, Andersson S, Bzhalava Z, Carlsten Thor A, et al.
- 10 Increasing participation in cervical screening by targeting long-term nonattenders:
- 11 Randomized health services study. *Int. J. Cancer* 2019;145, 11: 3033-9.
- 12 7. Cadman L, Waller J, Ashdown-Barr L, Szarewski A. Barriers to cervical screening in
- 13 women who have experienced sexual abuse: an exploratory study. *J Fam Plan Reprod Health*
- 14 *Care* 2012;38, 4:214-20.
- 15 8. Chorley AJ, Marlow LAV, Forster AS, Haddrell JB, Waller J. Experiences of cervical
- 16 screening and barriers to participation in the context of an organised programme: a systematic
- 17 review and thematic synthesis. *Psycho-Oncol* 2017;26, 2:161-72.
- 18 9. Leinonen MK, Campbell S, Klungsøyr O, Lönnberg S, Hansen BT, Nygård M.
- 19 Personal and provider level factors influence participation to cervical cancer screening: A
- 20 retrospective register-based study of 1.3 million women in Norway. *Prev. Med* 2017;94:31-9.
- 21 10. Hansen BT, Hukkelberg SS, Haldorsen T, Eriksen T, Skare GB, Nygard M. Factors
- 22 associated with non-attendance, opportunistic attendance and reminded attendance to cervical
- 23 screening in an organized screening program: a cross-sectional study of 12,058 Norwegian
- 24 women. *BMC Public Health* 2011;11:264.
- 25 11. Leinonen MK, Campbell S, Ursin G, Trope A, Nygard M. Barriers to cervical cancer
- 26 screening faced by immigrants: a registry-based study of 1.4 million women in Norway. *Eur.*
- 27 *J. Public Health* 2017;27, 5:873-9.
- 28 12. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al.
- 29 Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J. Pathol*
- 30 1999;189,1:12-9.
- 31 13. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial
- 32 Tropisms, and the Development of Neoplasia. *Viruses* 2015;7,7:3863-90.
- 33 14. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. *Lancet*
- 34 2019;393,10167:169-82.

- 1 15. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and  
2 reaching underscreened women by using HPV testing on self samples: updated meta-analyses.  
3 *BMJ* 2018;363:k4823.
- 4 16. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of  
5 self-sampled screening for HPV DNA: a systematic review and meta-analysis. *Sex Transm*  
6 *Infect* 2017;93,1:56-61.
- 7 17. Enerly E, Bonde J, Schee K, Pedersen H, Lonnberg S, Nygard M. Self-Sampling for  
8 Human Papillomavirus Testing among Non-Attendees Increases Attendance to the Norwegian  
9 Cervical Cancer Screening Programme. *PloS one* 2016;11,4:e0151978.
- 10 18. Broberg G, Gyrð-Hansen D, Miao Jonasson J, Ryd ML, Holtenman M, Milsom I, et  
11 al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term  
12 non-attendees as part of RACOMIP, a Swedish randomized controlled trial. *Int. J. Cancer*  
13 2014;134, 9:2223-30.
- 14 19. Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JM, et al.  
15 Home-based HPV self-sampling improves participation by never-screened and under-  
16 screened women: Results from a large randomized trial (iPap) in Australia. *Int. J. Cancer*.  
17 2016;139,2:281-90.
- 18 20. Kellen E, Benoy I, Vanden Broeck D, Martens P, Bogers JP, Haelens A, et al. A  
19 randomized, controlled trial of two strategies of offering the home-based HPV self-sampling  
20 test to non- participants in the Flemish cervical cancer screening program. *Int. J. Cancer*  
21 2018;143,4:861-8.
- 22 21. Tranberg M, Bech BH, Blaakaer J, Jensen JS, Svanholm H, Andersen B. Preventing  
23 cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening  
24 participation more than timely opt-in procedures - a randomized controlled trial. *BMC Cancer*  
25 2018;18,1:273.
- 26 22. Norwegian Directorate of Health. National Guidelines of Gynaecological Cancer  
27 [Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft]. 3. ed. 2021.  
28 Available: [https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft-](https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft-handlingsprogram)  
29 [handlingsprogram](https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft-handlingsprogram) [Accessed 08. Febr. 2022].
- 30 23. Tavassoli FA, Devilee P. eds. Pathology and Genetics of Tumours of the Breast and  
31 Female Genital Organs. WHO Classification of Tumours, 3rd ed. Vol. 4. Lyon: IARC Press;  
32 2003.

- 1 24. Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Hernández JC, Glazer-Livson S,  
2 et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active  
3 surveillance: systematic review and meta-analysis. *BMJ* 2018;360: k499.
- 4 25. Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching  
5 women who do not participate in the regular cervical cancer screening programme by offering  
6 self-sampling kits: a systematic review and meta-analysis of randomised trials. *Eur. J. Cancer*  
7 2015;51,16:2375-85.
- 8 26. Cadman L, Wilkes S, Mansour D, Austin J, Ashdown-Barr L, Edwards R, et al. A  
9 randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a  
10 self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening.  
11 *J Med Screen* 2015;22,1:28-37.
- 12 27. Lam JU, Rebolj M, Moller Ejegod D, Pedersen H, Rygaard C, Lynge E, et al. Human  
13 papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with  
14 electronic communication platforms. *Int. J. Cancer* 2017;140,10:2212-9.
- 15 28. Sanner K, Wikström I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal  
16 fluid at home combined with high-risk HPV testing. *Br. J. Cancer* 2009;101,5:871-4
- 17 29. Aasbø G, Solbrække KN, Waller J, Tropé A, Nygård M, Hansen BT. Perspectives of  
18 non-attenders for cervical cancer screening in Norway: a qualitative focus group study. *BMJ*  
19 *Open* 2019;9,8:e029505.
- 20 30. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide  
21 the prevention of cervical cancer. *Am J Obstet Gynecol* 2007;197,4:356.e1-.e3566.
- 22 31. Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N. Use of HC2 to triage  
23 women with borderline and mild dyskaryosis in the UK. *Br. J. Cancer* 2011;105,7:877-80.

24

25

26

27

**Table 1** Baseline characteristics of the women in the study population

Characteristic	Total, all arms n (%)		Control group n (%)		Opt-in n (%)		Opt-out n (%)	
Total invited	5,667	(100)	1,892	(100)	1,897	(100)	1,878	(100)
Age (years)								
36 to 45	1,318	(23.3)	435	(23.0)	433	(22.8)	450	(24.0)
46 to 55	1,520	(26.8)	497	(26.3)	520	(27.4)	504	(26.8)
56 to 65	1,961	(34.6)	663	(35.0)	653	(34.4)	646	(34.4)
66 to 69	868	(15.3)	298	(15.7)	292	(15.4)	278	(14.8)
Mean age (standard deviation)	54.3	(9.9)	54.5	(10.0)	54.4	(9.8)	54.1	(9.9)
Time since last screening test								
10 - 15 years	1,786	(31.5)	599	(31.7)	590	(31.1)	599	(31.9)
Over 15 years	1,950	(34.4)	650	(34.3)	658	(34.7)	642	(34.2)
Never screened	1,931	(34.1)	644	(34.0)	650	(34.2)	637	(33.9)
County								
Hordaland	2,106	(37.1)	707	(37.3)	710	(37.4)	689	(36.7)
Rogaland	1,705	(30.1)	568	(30.0)	563	(29.7)	574	(30.6)
Trøndelag	1,217	(21.5)	415	(21.9)	405	(21.3)	399	(21.2)
Vest-Agder	639	(11.3)	203	(10.7)	220	(11.6)	216	(11.5)
Total income (tertiles) <sup>1</sup>								
Low	1,877	(33.3)	622	(33.0)	632	(33.5)	623	(33.4)
Medium	1,878	(33.3)	610	(32.4)	659	(34.9)	609	(32.7)
High	1,877	(33.3)	650	(34.5)	595	(31.5)	632	(33.9)

<sup>1</sup>Total annual income (wage, welfare payment and capital income) from the most recent Statistics Norway registration during 2014-2018, by tertiles of the total study population. Data missing for 37 women

**Table 2** Screening participation among long-term non-attenders by intervention arm, and contrasts in any participation

	Control		Opt-in				Opt-out				Opt-in vs. Control		Opt-out vs. Control		Opt-out vs. Opt-in	
	N <sup>1</sup>	Clinician sample n (%) <sup>2</sup>	N <sup>1</sup>	Self-sample n (%) <sup>2</sup>	Clinician sample n (%) <sup>2</sup>	Total n (%) <sup>2</sup>	N <sup>1</sup>	Self-sample n (%) <sup>2</sup>	Clinician sample n (%) <sup>2</sup>	Total n (%) <sup>2</sup>	APD <sup>3</sup> (95% CI)	RPD <sup>4</sup> (95% CI)	APD <sup>3</sup> (95% CI)	RPD <sup>4</sup> (95% CI)	APD <sup>3</sup> (95% CI)	RPD <sup>4</sup> (95% CI)
<b>Total</b>	1,892	90 (4.8)	1,897	250 (13.2)	73 (3.8)	323 (17.0)	1,878	445 (23.7)	75 (4.0)	520 (27.7)	12.3 (10.3, 14.2)	3.6 (2.9, 4.5)	22.9 (20.7, 25.2)	5.8 (4.7, 7.2)	10.7 (8.0, 13.3)	1.6 (1.4, 1.8)
<b>Age group</b>																
36 – 45	435	35 (8.0)	433	63 (14.5)	17 (3.9)	80 (18.5)	450	121 (26.9)	27 (6.0)	148 (32.9)	10.4 (6.0, 14.9)	2.3 (1.6, 3.3)	24.8 (19.8, 29.9)	4.1 (2.9, 5.8)	14.4 (8.7, 20.1)	1.8 (1.4, 2.3)
46 – 55	497	23 (4.6)	519	66 (12.7)	23 (4.4)	89 (17.1)	504	122 (24.2)	21 (4.2)	143 (28.4)	12.5 (8.8, 16.3)	3.7 (2.4, 5.8)	23.7 (19.4, 28.1)	6.1 (4.0, 9.4)	11.2 (6.1, 16.3)	1.7 (1.3, 2.1)
56 – 65	662	22 (3.3)	653	91 (13.9)	24 (3.7)	115 (17.6)	646	141 (21.8)	20 (3.1)	161 (24.9)	14.3 (11.1, 17.5)	5.3 (3.4, 8.3)	21.6 (18.0, 25.2)	7.5 (4.9, 11.6)	7.3 (2.9, 11.8)	1.4 (1.1, 1.8)
66 – 69	298	10 (3.4)	292	30 (10.3)	9 (3.1)	39 (13.4)	278	61 (21.9)	7 (2.5)	68 (24.5)	10.0 (5.6, 14.4)	4.0 (2.0, 7.8)	21.1 (15.7, 26.6)	7.3 (3.8, 13.9)	11.1 (4.7, 17.5)	1.8 (1.3, 2.6)
<b>Time since last screening test</b>																
10 - 15 yrs	598	52 (8.7)	589	101 (17.1)	34 (5.8)	135 (22.9)	599	165 (27.5)	29 (4.8)	194 (32.4)	14.2 (10.1, 18.3)	2.6 (2.0, 3.6)	23.7 (19.3, 28.1)	3.7 (2.8, 4.9)	9.5 (4.4, 14.5)	1.4 (1.2, 1.7)
16 - 28 yrs	650	26 (4.0)	658	92 (14.0)	22 (3.3)	114 (17.3)	642	152 (23.7)	15 (2.3)	167 (26.0)	13.3 (10.1, 16.6)	4.3 (2.9, 6.5)	22.0 (18.3, 25.7)	6.5 (4.4, 9.7)	8.7 (4.2, 13.1)	1.5 (1.2, 1.9)
Never	644	12 (1.9)	650	57 (8.8)	17 (2.6)	74 (11.4)	637	128 (20.1)	31 (4.9)	159 (25.0)	9.5 (6.9, 12.2)	6.1 (3.4, 11.1)	23.1 (19.6, 26.6)	13.4 (7.5, 23.8)	13.6 (9.4, 17.7)	2.2 (1.7, 2.8)

<sup>1</sup> Number of women invited

<sup>2</sup> Number (%) of women screened, among women invited

<sup>3</sup> Absolute participation difference, i.e. percentage point participation difference in screening by any mode (intention to treat)

<sup>4</sup> Relative participation difference, i.e. relative risk of participation in screening by any mode (intention to treat)

**Table 3** Proportion of hrHPV at screening<sup>1</sup> among long-term non-attenders in total and by intervention arm

Type of HPV screening test	All women screened by HPV-test				Control				Opt-in				Opt-out			
	N	Any hr positive <sup>2</sup> n(%)	16/18 positive <sup>3</sup> n(%)	Other hr positive <sup>4</sup> n(%)	N	Any hr positive <sup>2</sup> n(%)	16/18 positive <sup>3</sup> n(%)	Other hr positive <sup>4</sup> n(%)	N	Any hr positive <sup>2</sup> n(%)	16/18 positive <sup>3</sup> n(%)	Other hr positive <sup>4</sup> n(%)	N	Any hr positive <sup>2</sup> n(%)	16/18 positive <sup>3</sup> n(%)	Other hr positive <sup>4</sup> n(%)
Total	913	100(11.0)	38(4.2)	60(6.6)	84	5(6.0)	0(0.0)	4(4.8)	314	34(10.8)	11(3.5)	23(7.3)	515	61(11.8)	27(5.3)	33(6.4)
Clin-sample	218	20(9.2)	5(2.3)	13(6.0)	84	5(6.0)	0(0.0)	4(4.8)	64	7(10.9)	2(3.1)	5(7.8)	70	8(11.4)	3(4.3)	4(5.7)
Self-sample	695	80(11.5)	33(4.8)	47(6.8)	-	-	-	-	250	27(10.8)	9(3.6)	18(7.2)	445	53(11.9)	24(5.4)	29(6.5)

<sup>1</sup> Women who attended clinician screening with cytology only (n=20) are not included. Six of these were in the control group, nine in the opt-in group and five in the opt-out group.

<sup>2</sup> Positive for one or more of the hrHPV-types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Two women (one control and 1 opt-out) were registered as any hrHPV positive, but lacked information on hrHPV-type

<sup>3</sup> Positive for HPV16 and/or 18, and may be positive for other hrHPV-types

<sup>4</sup> Positive for one or more of the hrHPV-types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68, but negative for 16/18

**Table 4** Attendance to triage among long-term non-attenders with a hrHPV positive self-sample<sup>1</sup>

	Total, n (%)	Opt-in, n (%)	Opt-out, n (%)
<b>Total</b>			
Positive tests	80 (100.0)	27 (100.0)	53 (100.0)
Had triage test <sup>2</sup>	63 (78.8)	21 (77.8)	42 (79.3)
Had triage test <sup>3</sup>	74 (92.5)	25 (92.6)	49 (92.5)
<b>Allocated gynaecologist</b>			
Positive tests	41 (100.0)	12 (100.0)	29 (100.0)
Had triage test <sup>2</sup>	31 (75.6)	10 (83.3)	21 (72.4)
Had triage test <sup>3</sup>	37 (90.2)	11 (91.7)	26 (89.7)
<b>Allocated RGP</b>			
Positive tests	39 (100.0)	15 (100.0)	24 (100.0)
Had triage test <sup>2</sup>	32 (82.1)	11 (73.3)	21 (87.5)
Had triage test <sup>3</sup>	37 (94.9)	14 (93.3)	23 (95.8)

<sup>1</sup>Positive clinician-samples do not require attendance for triage and are hence not included in this table

<sup>2</sup>Attended follow-up within 6 months of notification of positive HPV-result, at allocated physician

<sup>3</sup>Attended follow-up within 6 months of notification of positive HPV-result, regardless of where the exam took place

**Table 5** Histologically verified high-grade lesions<sup>1</sup> among long-term non-attenders in total and by intervention arm

	Total, n (%)	Control, n(%)		Opt-in, n(%)		Opt-out, n(%)		
		Clinician-sample	Total	Self-sample	Clin-sample	Total	Self-sample	Clin-sample
Invited	5,667	1,892	1,897			1,878		
Screened	933 (16.4)	90 (4.8)	323 (17.0)	250 (13.2)	73 (3.8)	520 (27.7)	445 (23.7)	75 (4.0)
Had histology result <sup>2</sup>	61 (1.1)	3 (0.2)	20 (1.1)	15 (0.8)	5 (0.3)	38 (2.0)	32 (1.7)	6 (0.3)
Had histology result <sup>3</sup>	61 (6.5)	3 (3.3)	20 (8.6)	15 (6.0)	5 (6.8)	38 (7.3)	32 (7.2)	6 (8.0)
CIN2+ detected <sup>2</sup>	33 (0.6)	1 (0.1)	12 (0.6)	9 (0.5)	3 (0.2)	20 (1.1)	17 (0.9)	3 (0.2)
CIN2+ detected <sup>3</sup>	33 (3.5)	1 (1.1)	12 (3.7)	9 (3.6)	3 (4.1)	20 (3.8)	17 (3.8)	3 (4.0)
CIN3+ detected <sup>2</sup>	31 (0.5)	1 (0.1)	10 (0.5)	7 (0.4)	3 (0.2)	20 (1.1)	17 (0.9)	3 (0.2)
CIN3+ detected <sup>3</sup>	31 (3.3)	1 (1.1)	10 (3.1)	7 (2.8)	3 (4.1)	20 (3.8)	17 (3.8)	3 (4.0)
Cervical cancer detected <sup>3</sup>	11 (1.2)	0 (0.0)	4 (1.2)	3 (1.2)	1 (1.4)	7 (1.3)	6 (1.3)	1 (1.3)

<sup>1</sup> CIN2, CIN3, ACIS or cancer

<sup>2</sup> Per cent of women invited

<sup>3</sup> Per cent of women screened



**Table 6** Histologically verified high-grade lesions (n, % of total) among screening test positive<sup>1</sup> women by triage mode

	Women screened by self-sampling and triaged by gynecologist <sup>2</sup>			Women screened by self-sampling and triaged by GP <sup>3</sup>			Women screened by clinician (any arm) or triaged outside study <sup>4</sup>			
	Total positive	16/18 positive <sup>5</sup>	Other HR positive <sup>6</sup>	Total positive	16/18 positive <sup>5</sup>	Other HR positive <sup>6</sup>	Total positive <sup>7</sup>	16/18 positive <sup>5</sup>	Other HR positive <sup>6</sup>	Cytology positive <sup>8</sup>
Total	31 (100.0)	14 (100.0)	17 (100.0)	32 (100.0)	9 (100.0)	23 (100.0)	34 (100.0)	13 (100.0)	17 (100.0)	2 (100.0)
Had histology result <sup>9</sup>	26 (83.9)	14 (100.0)	12 (70.6)	13 (40.6)	5 (55.6)	8 (34.8)	21 (61.8)	10 (76.9)	7 (41.2)	2 (100.0)
CIN2+ detected <sup>10</sup>	10 (32.3)	9 (64.3)	1 (5.9)	11 (34.4)	5 (55.6)	6 (26.1)	12 (35.3)	9 (69.2)	1 (5.9)	2 (100.0)
CIN3+ detected <sup>11</sup>	9 (29.0)	8 (57.1)	1 (5.9)	10 (31.3)	5 (55.6)	5 (21.7)	12 (35.3)	9 (69.2)	1 (5.9)	2 (100.0)
Cervical cancer detected	4 (12.9)	4 (28.6)	0 (0.0)	4 (12.5)	3 (33.3)	1 (4.3)	3 (8.8)	3 (23.1)	0 (0.0)	0 (0.0)

<sup>1</sup> Positive HPV test, or ASCUS+ for cytology

<sup>2</sup> Women from any self-sampling arm who were allocated to and attended gynecologist triage

<sup>3</sup> Women from any self-sampling arm who were allocated to and attended GP triage

<sup>4</sup> Women from any intervention arm who were screened by a clinician, and women from any self-sampling arm who self-sampled but were triaged outside the study

<sup>5</sup> Positive for HPV16 and/or 18, and may be positive for other high-risk HPV types

<sup>6</sup> Positive for any of the high-risk HPV-types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68, but not positive for 16/18

<sup>7</sup> Two women were registered as hr-HPV positive, but lacked information on hrHPV-type

<sup>8</sup> Did not have HPV screening test

<sup>9</sup> Registered with a histology diagnosis in the NCCSP/CRN databases

<sup>10</sup> CIN2, CIN3, ACIS or cancer

<sup>11</sup> CIN3, ACIS or cancer




Fig 1. Study flowchart. Excluded women were either not reached, not eligible or declined to participate in the study




Fig. 2. Participation rate (%) during six months following the invitation